[Metastatic prostate cancer]

Area of Science:

• Oncology
• Urology

Background:

• Metastatic prostate cancer is an incurable, hormonodependent malignancy.
• Current treatments offer palliative care, with a median survival of 3 years.
• Hormone resistance develops in a median of 2 years, limiting treatment efficacy.

Purpose of the Study:

• To review current treatment strategies for metastatic prostate cancer.
• To highlight the challenges of hormone resistance and symptom management.
• To emphasize the importance of quality of life in palliative care.

Main Methods:

• Review of existing literature on prostate cancer treatment.
• Analysis of therapeutic options including androgen blockade, radiotherapy, and chemotherapy.
• Evaluation of treatment side effects and symptom control.

Main Results:

• Androgen deprivation is the primary treatment, but resistance is common.
• Key symptoms include pain, urinary obstruction, and neurological complications.
• Side effects of androgen deprivation include impotency and osteoporosis.

Conclusions:

• Metastatic prostate cancer management is primarily palliative.
• Addressing hormone resistance and improving patient quality of life are critical.
• Multimodal treatment approaches are essential for symptom control.